SCHEMBL25657678

SCHEMBL25657678

Cc1ccc(C(OC(=O)C[C@H]2CCCCN2C(=O)OCC2c3ccccc3-c3ccccc32)(c2ccccc2)c2ccccc2Cl)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FABP7 O15540 1/20 0.36
▸ FABP5 Q01469 1/20 0.36
▸ PARP1 P09874 1/20 0.32
▸ DAGLA Q9Y4D2 3/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HCRTR2 O43614 2/20 0.32
▸ HCRTR1 O43613 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ ABHD6 Q9BV23 1/20 0.31
▸ GABRA1 P14867 1/20 0.31
▸ GABRG2 P18507 1/20 0.31
▸ GABRB3 P28472 1/20 0.31
▸ GABRA3 P34903 1/20 0.31
▸ GABRA2 P47869 1/20 0.31
▸ GABRB2 P47870 1/20 0.31
▸ ABHD11 Q8NFV4 1/20 0.31
▸ CHRM3 P20309 2/20 0.31
▸ PSEN1 P49768 1/20 0.31
▸ PSEN2 P49810 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25657679 0.98 FABP7 (0.36) FABP7FABP5PARP1ALDH1A1HCRTR2
SCHEMBL28773187 0.96 FABP7 (0.39) FABP7FABP5PARP1DAGLAHCRTR2
SCHEMBL25658698 0.91 FFAR2 (0.36) FABP7FABP5PARP1DAGLAHCRTR2
SCHEMBL25658700 0.91 FFAR2 (0.36) FABP7FABP5PARP1DAGLAHCRTR2
SCHEMBL25658705 0.89 FFAR2 (0.36) FABP7FABP5PARP1HCRTR2CHRM3
SCHEMBL25658708 0.89 FFAR2 (0.36) FABP7FABP5PARP1HCRTR2CHRM3
SCHEMBL26449252 0.88 FABP7 (0.38) FABP7FABP5TSHR
SCHEMBL14493095 0.79 KMT2A (0.43) FABP7FABP5TP53MDM2
SCHEMBL28773174 0.79 FABP5 (0.38) FABP7FABP5PARP1HCRTR2TP53
SCHEMBL24965899 0.79 MDM2 (0.41) TP53MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS FABP7 4602/4885FABP5 4094/4885PARP1 4115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback